TG Therapeutics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by TG Therapeutics, Inc. on March 9, 2017. The report details the entry into a material definitive agreement regarding a public offering of common stock.
Key Financial Metrics and Transaction Details
The Company entered into an underwriting agreement with Jefferies LLC to sell shares in a firm commitment underwritten public offering.
- Shares to be Sold: 5,128,206 shares of Common Stock (Firm Shares).
- Over-Allotment Option: Underwriters have a 30-day option to purchase up to an additional 769,230 shares.
- Public Offering Price: $9.75 per share.
- Expected Net Proceeds: Approximately $46.8 million (assuming no exercise of the over-allotment option and after deducting underwriting discounts, commissions, and estimated expenses).
- Estimated Offering Expenses: $225,000 total, including $100,000 in legal fees, $50,000 in accounting fees, $50,000 in printing, $10,000 in transfer agent fees, and $15,000 in miscellaneous expenses.
Material Changes
This filing represents a material change in the Company's capital structure and liquidity position due to the pending equity offering. The transaction is expected to close on March 14, 2017, subject to customary closing conditions.
Outlook, Risks, and Management Commentary
The offering is being made pursuant to an effective shelf registration statement on Form S-3. The filing includes a standard disclaimer that the representations and warranties in the Underwriting Agreement are for the benefit of the contracting parties and should not be relied upon by investors as characterizations of the actual state of facts or condition of the Company. No specific operational guidance or risk factors beyond standard underwriting terms are detailed in this specific 8-K text.
Key Facts for Investor Verification
- Verify the closing date of the offering (expected March 14, 2017) and whether the over-allotment option was exercised.
- Confirm the final net proceeds received by the Company after all deductions.
- Review the final prospectus supplement filed on March 9, 2017, for updated use of proceeds and risk factors.
- Check subsequent filings for any changes in the Company's cash position or debt levels resulting from this transaction.